Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.

①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.

cls.cnSep 4 09:29 ET

The recovery of the live pig market, ST Tianbang H1 turns loss into profit, and the pre-reorganization progresses as the company's debt decreases | interpretations

①ST Tianbang achieved a net profit of 0.174 billion yuan after non-deductible adjustments in Q2, compared to a net loss of 0.455 billion yuan after non-deductible adjustments for the company in Q1, indicating a significant improvement in the main business performance; ②During the reporting period, the company's food business grew significantly, but it remained in a loss state; ③The company made certain progress in reducing its debt, with total debt decreasing by 3.577 billion yuan since the beginning of the year and the debt ratio decreasing by 8.33 percentage points.

cls.cnAug 29 11:04 ET

The animal protection industry is under pressure, with pulike biological engineering,inc. H1 net profit falling by more than thirty percent. The pet track may become a new growth point. | Interpretations

① The net income of the animal protection industry in H1 generally declined, with Pulike Biological Engineering, Inc. declining by more than 30%, but the company's Q2 net income has narrowed compared to Q1; ② The company's pet track has made a breakthrough in H1 and may become a new growth point for future performance; ③ Looking ahead to the second half of the year, when the downstream animal husbandry industry's profits rebound, the upstream animal protection enterprises' profits will also show an upward trend.

cls.cnAug 29 10:37 ET

Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports

①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.

cls.cnAug 28 11:05 ET

Director of Shandong Jincheng Pharmaceutical Group investigated for suspected stock market manipulation. Q1 performance just turned around according to announcement.

On the evening of today, Shandong Jincheng Pharmaceutical Group announced that its actual controller and chairman, Zhao Yeqing, was under investigation for suspected illegal acts of market manipulation by the China Securities Regulatory Commission. Zhao Yeqing has been the chairman of Jincheng Pharmaceutical Group for 13 years. The last time he appeared in public was at the 3rd China Pharmaceutical and Chemical Conference two days ago. In Q1 of 2024, Jincheng Pharmaceutical Group has shown a good trend of reversing last year's poor performance.

cls.cnAug 16 10:45 ET

Shanghai Pharmaceuticals Holding Co., Ltd Goes Ex Dividend on Monday

Seeking AlphaJul 14, 2023 14:38 ET